All Posts By

Gayle Mineo

Cellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors

By Portfolio News, BobcatBio
THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and…
Read More

Wellsheet continues momentum with health systems across US, brings AI to San Juan Regional Medical Center

By Portfolio News, Wellsheet
Becomes go-to AI intelligence layer and clinical decision support tool across 100+ hospitals NEWARK, N.J., Feb. 19, 2026 /PRNewswire/ -- Wellsheet, a leader in AI clinical workflows and operations, was recently named one of 2025's most promising startups. Wellsheet is gaining traction as hospitals grapple with clinician burnout and data overload. Its technology is live…
Read More

Keriton Announces Acquisition by Natus Sensory to Accelerate Adoption of Its Feeding Management Platform

By Portfolio News, Keriton
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Keriton, a market leader in innovative cloud-based software that streamlines breast milk and formula management and supports safe feeding practices, announced today that it has been acquired by Natus Sensory, a global leader in sensory and newborn care solutions. Keriton will become part of Natus Sensory’s Newborn Care portfolio,…
Read More

Strados Labs Announces Study Evaluating Remote Lung Sound Monitoring to Predict COPD Exacerbations

By Portfolio News, Strados
The SHORE study, in collaboration with Jefferson Health, will assess the feasibility of home-based, continuous monitoring of cough and lung sounds including wheeze and rhonchi following COPD exacerbations. Enrollment started in January. PHILADELPHIA, PA / ACCESS Newswire / January 28, 2026 / Strados Labs, a medical technology company advancing respiratory care through wearable…
Read More

IVIEW Therapeutics’ Innovative Gene Therapy GVB-2001 Treats First Primary Open-Angle Glaucoma Patient

By Portfolio News, iView Therapeutics
IVIEW Therapeutics announced today that its innovative gene therapy candidate GVB-2001 has successfully completed treatment of the first patient with primary open-angle glaucoma (POAG), marking a key clinical milestone and opening a new chapter for glaucoma management unconstrained by patient-specific genetic backgrounds. The procedure was performed under the direction of…
Read More

Insmed Provides Clinical and Business Update

By Portfolio News, Opsidio
Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM),…
Read More

Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module

By Portfolio News, Atalan
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience Analytics PHILADELPHIA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Atalan, the world’s first Clinical Retention Intelligence (CRI) platform, today announced a strategic partnership with Accrete Health Partners, the venture arm of Bon Secours…
Read More

ImmunoGenesis Receives $10.8 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Accelerate the Clinical Development of IMGS-001 for Patients with Immune-Excluded Tumors with High Unmet Need

By Portfolio News, ImmunoGenesis
IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Houston, Texas, Dec. 4, 2025 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded…
Read More

Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations

By Portfolio News, Latus
LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore the potential of LTS-101 to address a high unmet medical need PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company…
Read More

IVIEW Therapeutics’ Investigational Ophthalmic Drug IVIEW-1201D Has Its Phase III IND Cleared by the FDA for Adenoviral Conjunctivitis

By Portfolio News, iView Therapeutics
IVIEW Therapeutics (“IVIEW”) today announced that its investigational ophthalmic drug, IVIEW-1201D, has received U.S. Food and Drug Administration (FDA) Phase III IND clearance for the treatment of adenoviral conjunctivitis. This important milestone marks the program’s entry into a new phase of global, pivotal clinical development and represents a major step…
Read More